Document Detail

A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.
MedLine Citation:
PMID:  23038754     Owner:  NLM     Status:  MEDLINE    
Alzheimer's disease (AD), one of the leading neurodegenerative disorders of older adults, which causes major socioeconomic burdens globally, lacks effective therapeutics without significant side effects. Besides the hallmark pathology of amyloid plaques and neurofibrillary tangles (NFTs), it has been reported that cyclin-dependent kinase 5 (Cdk5), a critical neuronal kinase, is hyperactivated in AD brains and is, in part, responsible for the above pathology. Here we show that a modified truncated 24-aa peptide (TFP5), derived from the Cdk5 activator p35, penetrates the blood-brain barrier after intraperitoneal injections, inhibits abnormal Cdk5 hyperactivity, and significantly rescues AD pathology (up to 70-80%) in 5XFAD AD model mice. The mutant mice, injected with TFP5 exhibit behavioral rescue, whereas no rescue was observed in mutant mice injected with either saline or scrambled peptide. However, TFP5 does not inhibit cell cycle Cdks or normal Cdk5/p35 activity, and thereby has no toxic side effects (even at 200 mg/kg), a common problem in most current therapeutics for AD. In addition, treated mice displayed decreased inflammation, amyloid plaques, NFTs, cell death, and an extended life by 2 mo. These results suggest TFP5 as a potential therapeutic, toxicity-free candidate for AD.
Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Related Documents :
24324824 - Folic acid protects against lipopolysaccharide-induced preterm delivery and intrauterin...
24998504 - Mucoactive effects of naringin in lipopolysaccharide-induced acute lung injury mice and...
12490134 - Induction of anti-metallothionein antibody and mercury treatment decreases bone mineral...
23921304 - (-)-epigallocatechin gallate inhibits tnf-α-induced pai-1 production in vascular endot...
6802524 - Serum lysosomal acid hydrolase activities in graves' disease.
10882144 - Absence of response to human parathyroid hormone in athymic mice grafted with human par...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural     Date:  2012-10-04
Journal Detail:
Title:  FASEB journal : official publication of the Federation of American Societies for Experimental Biology     Volume:  27     ISSN:  1530-6860     ISO Abbreviation:  FASEB J.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-03     Completed Date:  2013-03-07     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  8804484     Medline TA:  FASEB J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  174-86     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alzheimer Disease / prevention & control*
Amino Acid Sequence
Enzyme Activators / pharmacology*
Mice, Transgenic
Molecular Sequence Data
Nerve Tissue Proteins / chemistry,  pharmacology*
Reg. No./Substance:
0/Enzyme Activators; 0/Nerve Tissue Proteins; 0/neuronal Cdk5 activator (p25-p35)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Methylation of RASSF1A gene promoter is regulated by p53 and DAXX.
Next Document:  Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice.